MedTrace Logo

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

NCT03028974 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2018-12-14

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.

Conditions

Interventions

BIOLOGICAL

Fluzone®

Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine

BIOLOGICAL

FluMist®

FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia Dekker, MD · Stanford University

  • Harry Greenberg, MD · Stanford University

  • Xiaosong He, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-17
Primary Completion
2017-11-20
Completion
2017-11-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03028974 on ClinicalTrials.gov